-20°C or colder in a manual defrost freezer. Avoid freeze-thawing.
Biosafety Level
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Introduction
Cell Line Description:
This cell line was initiated from a primary ductal carcinoma on October 13, 1995, and took 11.5 months to establish. The tumor was classified as TNM Stage IIB, grade 3 BRCA1 analysis revealed that the cell line is homozygous for the BRCA1 5382C mutation, whereas the lymphoblastoid cell line derived from the same patient is heterozygous for the same mutation.? This mutation was present in two other family members; an identical sister also developed breast cancer. The cell line has an acquired mutation of TP53 with wild-type allele loss; an acquired homozygous deletion of the PTEN gene, and loss of heterozygosity at multiple loci known to be involved in the pathogenesis of breast cancer.
The cells are negative for expression of Her2-neu and for expression of p53. HCC1937 is positive for the epithelial cell-specific marker, Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR).? DNA isolated from an EBV-transformed lymphoblastoid cell line (HCC1937BL) from the same patient is available as ATCC CRL-2337D.
Quality Control Specifications
DNA Quality Control Information:
· > 100 kb in size by agarose gel electrophoresis
· No RNA detected in the agarose gel
· A260/A280 ratio 3 1.8
· Tested and verified for PCR amplification and restriction digestion.
